Memphasys Ltd (AU:MEM) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Memphasys Limited has appointed Lindley Edwards as the new Non-Executive Chairperson, succeeding Robert Cooke, as the company nears the completion of its clinical trial for the Felix™ System. Edwards brings over 30 years of experience in financial services and corporate governance, aiming to steer Memphasys towards global commercialisation of its sperm separation technology and RoXsta™ System. These advancements are set to strengthen Memphasys’ position in the fertility and biotechnology markets.
For further insights into AU:MEM stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Nvidia Stock Could Take a Beating from Supply Snags on Blackwell Chips
- ‘This Is Just Pure Hype,’ Says Top Investor About Tesla Stock
- Will Palantir Stock Crash to $28? Jefferies Sounds the Alarm
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
